Abstract: The present invention relates to a topical agent that binds specifically to myelin basic protein and its method of use and determining myelination in the subject by detecting the agent present in the subject. A kit containing the agent or its derivatives for use in detecting myelin basic protein is also provided.
Type:
Grant
Filed:
August 14, 2020
Date of Patent:
August 22, 2023
Assignee:
General Electric Company
Inventors:
Cristina Abucay Tan Hehir, Tiberiu Mircea Siclovan, Victoria Eugenia Cotero
Abstract: The present invention relates to 99mTc-maraciclatide radiopharmaceutical compositions, which are stabilised with a radioprotectant. Also described are kits for the preparation of the radiopharmaceutical compositions, as well as methods of preparing such compositions from the kit. The invention also includes methods of imaging the mammalian body using the radiopharmaceutical compositions.
Abstract: Compounds are described which include polyvalent ligands linked to a cyclodextrin scaffold which exhibit strong binding affinities for lanthanides and favorable characteristics with respect to altering the relaxation time of coordinated water molecules. The compounds are useful as contrast agents in applications such as magnetic resonance imaging. The polyvalent ligands are also useful in applications requiring chelation of metal ions in other applications such as water treatment, sequestration of metal ions and treatment of diseases or conditions caused by exposure to toxic or radioactive metal ions.
Abstract: An ophthalmic composition comprising Indigo Carmine, or Indigo Carmine and Trypan Blue, for identification of intraocular structures and membranes within the eye, and methods of delivering and using the same, for surgical treatments of the eye, including glaucoma and cataract surgery.
Abstract: Methods for in vivo immunoimaging including: (a) administering a labeled-antibody conjugate to a subject, wherein the labeled-antibody conjugate includes: an antibody that specifically recognizes and binds to IFN-?, and a detection label conjugated to the antibody, wherein the detection label is a radionuclide tracer or tluorophore; and (b) detecting the presence of the radiolabeled-antibody conjugate in the subject in vivo by imaging. Embodiments of the present disclosure are directed to labeled-antibody conjugates and therapeutic radionuclide-antibody conjugates.
Abstract: Bifunctional molecules having first and second alpha-synuclein binding agents coupled by a linker are disclosed. The bifunctional molecules have potential utility in the diagnosis, treatment and/or prophylaxis of disorders in which alpha-synuclein is implicated, including Parkinson's disease. Methods of making and using the bifunctional molecules are disclosed.
Type:
Grant
Filed:
September 8, 2017
Date of Patent:
April 25, 2023
Assignee:
University of Saskatchewan
Inventors:
Joseph Kakish, Edward Krol, Jeremy Lee, Kevin Allen
Abstract: The presently disclosed subject matter provides compositions, kits, and methods comprising imaging agents that can detect Programmed Death Ligand 1 (PD-L1). The presently disclosed imaging agents can be used to detect diseases and disorders, such as cancer, infection, and inflammation, in a subject.
Type:
Grant
Filed:
December 21, 2017
Date of Patent:
March 21, 2023
Assignee:
The Johns Hopkins University
Inventors:
Sridhar Nimmagadda, Martin Pomper, Samit Chatterjee, Wojciech Lesniak, Dhiraj Kumar
Abstract: The present invention relates to the use of radiopharmaceuticals having a radioactive half-life of less than 21 minutes, such as oxygen-15 labeled water (H215O) in blood flow imaging using PET (Positron emission tomography) scanning technology. The invention also relates to the use of a system for preparing and injecting boluses of such radiopharmaceuticals.
Type:
Grant
Filed:
December 23, 2020
Date of Patent:
March 21, 2023
Assignee:
MedTrace Pharma A/S
Inventors:
Martin Stenfeldt, Rune Wiik Kristensen, Peter Larsen
Abstract: Described herein are nanoprobes comprising ultrasmall aminated and cRGDY-conjugated nanoparticles labeled with Zirconium-89 (89Zr) and methods of their use. The provided compositions are renally clearable and possess suitable blood circulation half-time, high tumor active targeting capability, dominant renal clearance, low liver accumulation, and a high tumor-to-background ratio. The described nanoprobes exhibit great potential as “target-or-clear” tracers to human subjects for systemic targeted imaging (or treatment) of cancer.
Type:
Grant
Filed:
May 17, 2018
Date of Patent:
January 24, 2023
Assignees:
Memorial Sloan Kettering Cancer Center, Cornell University
Inventors:
Michelle S. Bradbury, Feng Chen, Ulrich Wiesner, Kai Ma
Abstract: The invention relates to a novel radiopharmaceutical that inhibits the prostate-specific membrane antigen (iPSMA), containing hydrazinonicotinamide (HYNIC) as a critical chemical group in increasing in the lipophilicity of the molecule for binding to the hydrophobic sites of the PSMA, combined with the conventional use of HYNIC as a chelating agent for radiometal 99mTc, in which the ethylenediaminetetraacetic acid (EDDA) is used to complete the coordination sphere of the radiometal. The novel radiopharmaceutical 99mTc-EDDA/HYNIC-iPSMA detects, with high affinity and sensitivity in vivo, the overexpressed PSMA protein in prostate cancer cells using SPECT molecular imaging techniques in nuclear medicine. The aim of the invention is to provide a novel specific radiopharmaceutical (radiopharmaceutical for molecular targets) for SPECT, with high sensitivity for the detection of tumours with overexpression of PSMA.
Type:
Grant
Filed:
December 28, 2020
Date of Patent:
January 10, 2023
Assignee:
Instituto Nacional de Investigaciones Nucleares
Inventors:
Guillermina Ferro Flores, Blanca Eli Ocampo Garcia, Clara Leticia Santos Cuevas, Myrna Alejandra Luna Gutiérrez, Erika Patricia Azorin Vega, Nallely Patricia Jiménez Mancilla
Abstract: The present invention relates to an emulsion composition for chemoembolization comprising a nanoparticle comprising a drug and a biocompatible polymer, a water-soluble contrast agent and a water-insoluble contrast agent, and a water-insoluble drug as well as an aqueous drug can be administered in a form of stable emulsion, and drugs are slowly released, thereby enhancing the effect of chemoembolization.
Abstract: Provided herein are compositions and methods for stabilizing coelenterazine and analogs or derivatives thereof, and for improving the solubility and reconstitution efficiency of coelenterazine and analogs and derivatives thereof.
Type:
Grant
Filed:
October 3, 2019
Date of Patent:
December 27, 2022
Assignee:
Promega Corporation
Inventors:
Melanie Dart, Thomas Smith, Thomas Kirkland, Thomas Machleidt, Keith Wood
Abstract: Methods of ex vivo labeling of a biological material for in vivo imaging, methods of labeling a biological material in vivo, methods for preparing a labeling agent, and methods for in vivo imaging of a subject using a biological material labeled with a labeling agent are disclosed. In one non-limiting example, the biological material is selected from cells and the labeling agent is a 89Zr-Desferrioxamine-NCS labeling agent.
Type:
Grant
Filed:
March 7, 2016
Date of Patent:
December 27, 2022
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Aditya Bansal, Timothy R. DeGrado, Mukesh K. Pandey
Abstract: The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.
Type:
Grant
Filed:
December 6, 2019
Date of Patent:
December 20, 2022
Assignees:
Universite Claude Bernard Lyon I, Nano-H, Centre National de la Recherche Scientifique—CNRS, Universite Grenoble Alpes, Universite de Bordeaux
Abstract: Provided herein are methods and materials that allow targeting and imaging of interactions between probes and targets. In some embodiments, the probes include nanoscale materials with embedded solutions that can be used to measure physical enhancement by materials under X-ray irradiation. In some embodiments, the methods of the present invention include delivering a probe material to a target that can have a delivered donor material. In some embodiments, methods of the present invention include irradiating the target and determining an optical change in the probe characteristic of a physical enhancement.
Type:
Grant
Filed:
July 20, 2018
Date of Patent:
December 20, 2022
Assignee:
The Regents of the University of California
Abstract: In one aspect, the invention comprises compounds that bind to the synaptic vesicle protein SV2A and that can be useful as radiotracers for positron emission tomography. In another aspect, the invention comprises methods of imaging the brain, measuring synaptic density or diagnosing neurological diseases such as Alzheimer's disease, psychiatric disorders such as depression, and metabolic disorders such as diabetes comprising detecting the compounds of the invention by positron emission tomography (PET).
Abstract: The present invention relates to methods of forming metal-pyridine derivative complexes using pericyclic reactions with metal-1,2,4-triazine derivative complexes and a dienophile as the reactants. The reactants are bioorthogonal and the methods are particularly useful in preparing imaging agents.
Abstract: The invention relates to amphiphilic dye-coated inorganic nanoparticle clusters and uses thereof. Specifically, the invention relates to cyanine and/or cyclic tetrapyrrole dye-coated metallic nanoparticle clusters for use in medical imaging and treatments.
Type:
Grant
Filed:
July 5, 2018
Date of Patent:
September 20, 2022
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Inventors:
Andrew Tsourkas, Jayesh Thawani, Ahmad Amirshaghaghi, Lesan Yan, Zhiliang Cheng
Abstract: The present invention is related to short-term renal injury models and methods for creating these models. The models and methods can be used for identifying, testing or characterizing candidate molecules with respect to their suitability to treat renal injury. The methods comprise a step of inducing, in a test subject, renal injury by administering subcutaneously a bolus of a renal injury inducer, in a dosage sufficiently high to induce renal injury. Different types of readout for renal injury are provided such as albumin creatinine ratio (ACR) determined in a urine sample taken from the subject, or the development of transcutaneous fluorescence after injection of a fluorescent molecule. Based on the readout the degree of renal injury and/or alteration of GFR can be determined.